Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.

Crohns Colitis 360 · 2020 · PMC9808818 · PMID 36776497

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The box plot of RHI score showed a decreasing trend over time regardless of treatment (KHK4083 or placebo) with no dose dependency over time ( Fig. 4B ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.